Phillip M. Pierorazio, MD is a board-certified urologist with training and expertise in urologic cancers. His expertise includes all malignancies of the urinary tract, but his clinical and academic practice focuses on kidney cancer (renal cell carcinoma), testicular cancer (germ cell tumors), upper tract urothelial cancer, and prostate cancer.
Dr. Pierorazio’s research team includes basic science researchers, statisticians, and other urologists both inside and outside Penn Medicine. Their focus is on access to care, cancer biomarkers, improving outcomes for complex surgeries, evaluating the quality of care through a cancer journey, the quality of life for cancer survivors, and minimizing the impact of surgical treatments.
Dr. Pierorazio runs the Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry — one of the largest active surveillance registries for patients with small kidney tumors. Additionally, he is involved in several national guideline panels, including both the American Urological Association (AUA) and National Comprehensive Cancer Network (NCCN) Guidelines Committees, for Kidney, Testicular, and Upper Tract Urothelial Cancer.
